Affimed Shifts Attention To Risky Combination Therapy With NK Cells For T-Cell Lymphoma Seeking Alpha, 17 Feb 2023 Follow Summary Affimed has decided to focus on testing AFM13 in combination with Artiva's AB-101 NK cell product for the…